Journal article

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

Jessica Ramsay, Julie Marsh, Alisa Pedrana, Nada Andric, Richard Norman, Wendy Cheng, Steve Webb, Nikolajs Zeps, Matthew Bellgard, Todd Graves, Margaret Hellard, Tom Snelling

BMC Infectious Diseases | BMC | Published : 2020


BACKGROUND: Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma. Australia is committed to eliminating hepatitis as a public health threat by 2030 set by the World Health Organization. However, since the introduction of funded DAA treatment, uptake has been suboptimal. Australia needs improved strategies for testing, treatment uptake and treatment completion to address the persisting hepatitis C pu..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

This work was supported by the Government of Western Australian, Department of Health Research Translation Projects (RTP) program (Research Translation Project 2016 (Round 10)). The funding source had no role in the design of PLATINUM C and will not have any role in the execution, analyses, interpretation of the data, or decision to submit results.